Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 14/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.51 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.51 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.51 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17698979 | 0.82 | SLC22A12 (0.60) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL1767681 | 0.81 | SLC22A12 (0.58) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL4029025 | 0.81 | SLC22A12 (0.58) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL29536289 | 0.81 | SLC22A12 (0.58) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL6732196 | 0.79 | SLC22A12 (0.57) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL1427884 | 0.79 | CA1 (0.48) | MEN1KMT2ACYP2C9GAA | |
| SCHEMBL416572 | 0.78 | ALDH1A1 (0.42) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL3769130 | 0.78 | SLC22A12 (0.70) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL29418255 | 0.78 | MEN1 (0.56) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL302570 | 0.78 | MEN1 (0.56) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741932-B2 | Imidazopyridine derivatives | Piramal Enterprises Limited (IN) | 2014-06-03 | — | — | US | claimed |
| US-20120232072-A1 | IMIDAZOPYRIDINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-09-13 | — | — | US | claimed |
| EP-2496577-A1 | IMIDAZOPYRIDINE DERIVATIVES | Piramal Life Sciences Limited (IN) | 2012-09-12 | — | — | EP | claimed |
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | claimed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | claimed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | claimed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | claimed |
| CN-118184582-A | 4-Seleno-1-benzenesulfonyl pyrazole compound and electrochemical synthesis method and application thereof | 延安大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-117186769-B | Wax-proof scale-proof anticorrosive paint and preparation method thereof | 陕西鑫宏宇防腐科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117186769-A | Wax-proof scale-proof anticorrosive paint and preparation method thereof | 陕西鑫宏宇防腐科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-113387771-A | Preparation method of chiral fluoroalkyl ternary carbocyclic compound | 东北师范大学 | 2021-09-14 | — | — | CN | disclosed |
| CN-106608788-B | A kind of preparation method of mild diazomethane derivative | 东北师范大学 | 2019-05-14 | — | — | CN | disclosed |
| CN-106608788-A | Preparation method of mild diazomethane derivative | 东北师范大学 | 2017-05-03 | — | — | CN | disclosed |
| EP-1827446-A2 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES, INC. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006062898-A2 | COMPOUNDS AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES | SIGA TECHNOLOGIES, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| WO-2004034288-A1 | THE THREE-DIMENSIONAL CRYSTAL STRUCTURE OF BCATC COMPLEXES AND METHODS OF USE THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-22 | — | — | WO | disclosed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | SLC22A12 350/4885MEN1 3229/4885KMT2A 911/4885 |
| US-20120232072-A1 | IMIDAZOPYRIDINE DERIVATIVES | IL6, IL6ST, STAT3 | SLC22A12 4801/4885MEN1 4479/4885KMT2A 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.